Every Major Anti-Aging Drug Ranked: What the Evidence Actually Shows

Aging is the single strongest risk factor for cardiovascular disease, cancer, type 2 diabetes, and neurodegeneration — and geroscience now recognizes it as a potentially modifiable biological process rather than an inevitable destiny. This 2026 structured narrative review, authored by researchers at Cardinal Stefan Wyszynski University and Maria Skłodowska-Curie Medical University in Warsaw, synthesizes preclinical and clinical evidence for pharmacological geroprotection across the most important molecular targets identified to date. The search covered PubMed, Scopus, and Web of Science from January 2010 through March 2026, guided by SANRA (Scale for the Assessment of Narrative Review Articles) methodology and prioritizing randomized trials, meta-analyses, and human biomarker studies while explicitly distinguishing mechanistic plausibility from validated clinical benefit.

The mTOR pathway receives the strongest preclinical grading. Rapamycin reproducibly extended both median and maximal lifespan in mice — even when initiated late in life — and rapalogs have demonstrated immunomodulatory effects and SASP suppression in early human studies. However, clinical investigations have primarily evaluated safety or disease-specific outcomes rather than validated biological aging endpoints, and chronic mTOR inhibition raises concerns around immune suppression and dyslipidemia. AMPK activation via metformin is next in translational maturity: observational data associate long-term metformin use with reduced cancer incidence, lower cardiovascular event rates, and all-cause mortality benefits even compared with non-diabetic controls. The TAME (Targeting Aging with Metformin) trial — the first regulatory-sanctioned trial to use multimorbidity onset as a primary endpoint — is now underway and is expected to provide the first rigorous human evidence for broad geroprotection by any drug.

Cellular senescence and senolytics represent another priority axis. SASP-positive senescent cells drive inflammaging and extracellular matrix degradation; the senolytic combination of dasatinib plus quercetin (D+Q) and navitoclax have shown physical performance improvements and senescent-cell burden reductions in preclinical models. Early pilot trials in humans with idiopathic pulmonary fibrosis and diabetic kidney disease reported reductions in circulating p21, p16, and senescence-associated secretome markers, though samples were small (n = 9–14) and long-term outcomes remain unmeasured. The review emphasizes that biomarker reduction alone is not equivalent to clinically meaningful benefit.

SGLT2 inhibitors and GLP-1 receptor agonists have established cardiovascular and renal outcome trial data — empagliflozin and dapagliflozin reduced major adverse cardiac events and hospitalization for heart failure in large RCTs — and emerging evidence suggests pathway-level effects on mitochondrial biogenesis, AMPK activation, and senescence markers. However, the authors stress these remain indirect, disease-context-specific benefits rather than demonstrated geroprotection. NAD+ precursors (NMN and NR) restore intracellular NAD+ levels, activate sirtuins, and improve mitochondrial function in rodent aging models, but human RCTs — generally 8–12 weeks, n = 20–60 — have shown only modest or inconsistent effects on physical performance, insulin sensitivity, and aging biomarkers. Taurine, which declines ~80% in circulating levels from youth to old age, extended median lifespan by 10–12% in middle-aged mice across multiple cohorts; a brief human supplementation study showed favorable metabolic effects but no aging endpoint data yet exist.

Across all interventions, the review identifies shared obstacles: no universally accepted biomarker or clinical endpoint for biological aging, heterogeneous treatment-response likely driven by baseline biology and genetics, uncertainty about optimal timing (prevention vs. treatment), and the near-complete absence of long-term safety data for preventive use in healthy populations. The authors call for adequately powered RCTs integrating epigenetic clocks, functional healthspan measures, and multimorbidity endpoints alongside rigorous biomarker-guided patient stratification. They also flag the commercial hype problem — several initially promising findings in aging research have not replicated or showed substantially smaller effects than first reported — underscoring why methodological rigor and independent validation are non-negotiable as geroprotective pharmacology moves toward clinical practice.